



tandard-dose chemotherapy is the first-line
therapy for patients with non-Hodgkin’s
lymphoma (NHL) and Hodgkin’s disease
(HD).1,2 The concept of dose intensity (as the
amount of drug given for unit time) has gained
credence as a critical factor in the outcome of
treatment.3
The definition of dose intensity implies that
both delay in drug administration and dose
reduction influence dose intensity in the same
way. Neutropenia is the most important cause
of delay in chemotherapy administration and of
dose reduction. Moreover, infections secondary
to neutropenia represent the most important
cause of death in patients undergoing chemo-
therapy.4
Human recombinant granulocyte colony-
stimulating factor (G-CSF) administered in
vivo induces a dose-dependent increase in cir-
culating neutrophils.5 G-CSF given after cyto-
toxic chemotherapy could provide protection
from neutropenia-related infections and allow
increases in dose intensity. However, G-CSF, by
promoting proliferation of hematopoietic prog-
enitor cells, may increase their sensitivity to
cytotoxic drugs and thus increase the risk of
severe leuko-thrombocytopenia when repeated
cycles of chemotherapy plus G-CSF are deliv-
ered.6 In order to prevent hematopoietic toxici-
ty due to detrimental effects on regenerating
progenitors, G-CSF should be optimally com-
bined with chemotherapy. 
It was the aim of the present study to evaluate
the effect on leukocyte and platelet counts of G-
CSF given in conjunction with repeated chemo-
therapy courses. 
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ABSTRACT
In this study, nine patients with non-Hodgkin’s lymphoma (n=6) and Hodgkin’s disease (n=3)
receiving different cytotoxic chemotherapy regimens were given granulocyte colony-stimulating
factor (G-CSF) (5 eg/kg/day) from 48 hours after the end of chemotherapy to 48 hours before the
next chemotherapy administration. The decrease in mean absolute neutrophil counts (ANC) and in
mean platelet (Plt) counts was not significant when pre-therapy counts were compared with post-
therapy ones (p < 0.375 and p > 0.4, respectively). The mean actual dose intensity was 92% (range
68-100%). G-CSF treatment after chemotherapy reduces neutropenia and permits administration
of the full chemotherapy program. A wash-out period between G-CSF treatment and chemotherapy
administration is needed to prevent the detrimental effect of chemotherapy on leukocyte and
platelet recovery when repeated cycles of cytotoxic drugs and G-CSF are administered.
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Patients and Methods
Patients
Nine patients (6 males and 3 females) aged
between 18 and 60 years (median 45 years) with
histologically documented NHL (n=6) and HD
(n=3) were enrolled in this study. The charac-
teristics of the patients are detailed in Table 1. 
Treatment
Patients with NHL were treated with the
CEMP or VACOP-B regimens, while HD
patients received the MOPP-ABV regimen
(Table 1). A total of 84 chemotherapy cycles
were administered in the nine patients. G-CSF,
at a dose of 5 eg/kg/day administered as a daily
single subcutaneous injection, was started 48
hours after the end of each chemotherapy cycle
and discontinued 48 hours before the subse-
quent chemotherapy treatment. All patients
received prophylactic ciprofloxacin 500 mg
twice daily and fluconazol 50 mg twice daily.
Doxorubicin, cyclophosphamide, etoposide,
mitoxantrone, mechlorethamine and procar-
bazine dosages were reduced by 50% if the
absolute neutrophil count (ANC) on the
planned day of treatment was > 0.5u109/L and
less than 1.0u109/L, or if the platelet count (Plt)
was >60u109/L and less than 90u109/L. If on the
planned day of treatment the ANC was less than
0.5u109/L or Plt less than 20u109/L, chemother-
apy was delayed by 7 days. Patients with bone
marrow infiltration by lymphoma received
100% of the dose independently of leukocyte
and platelet counts. 
Study procedures
On the day planned for the start of chemo-
therapy, all patients underwent a full blood
count including differential, and a biochemical
profile evaluation including creatinine and liver
function test. World Health Organization
(WHO) criteria were used to evaluate toxiciy.
Chemotherapy dose analysis was performed uti-
lizing the actual dose intensity expressed as a
percentage of standard dose intensity.3,7 Response
was evaluated in accordance with standard rec-
ommendations.8
Statistical analysis
Analysis was performed with the chi-square
test to evaluate statistical significance.
Results
ANC. The mean ANC at the beginning of the
first and the last chemotherapy cycles were
4.5u109/L (range 2.5-6.7u109/L) and 4.1u109/L
(range 1.4-6.3u109/L), respectively (Table 2).
The decrease in mean ANC was not significant
(p < 0.375). In the 84 cycles performed during
this study, WHO grade III neutropenia was
observed in 6 cycles (7%) and grade IV in 7
cycles (8%). During G-CSF administration
increases in circulating myelocytes, metamyelo-
cytes and monocytes were observed.
Platelets. The mean Plt counts at the begin-
ning of the first and the last chemotherapy
cycles were 261u109/L (range 192-338u109/L)
and 251u109/L (range 104-566u109/L), respec-
tively (Table 2). The decrease in mean Plt counts
was not significant (p > 0.4). In the 84 cycles
performed during this study, WHO grade II
thrombocytopenia was observed in 7 cycles
Table 1. Characteristics of  the patients included in the study.
Case Age/Sex Histology Status prior Stage Treatment
to treatment
1 39/F LnH c.c.a Progression IV* CEMPd
2 60/F LnH c.b Recurrence III CEMP
3 35/M LnH c. Presentation III CEMP
4 48/M LnH c.c. Progression III CEMP
5 52/M LnH c.c. Progression IV* VACOP-Be
6 48/M LnH c.c. Presentation III VACOP-B
7 59/F HD n.s.c Presentation III MOPP-ABVf
8 18/M HD n.s. Presentation IV* MOPP-ABV
9 48/M HD n.s. Presentation III MOPP-ABV
ac.c.: centrocytic/centroblastic diffuse; bc.: centroblastic diffuse; cn.s.: nodular sclerosis;
dCEMP: cyclophosphamide 650 mg/m2 iv day 1, etoposide 150 mg/m2 iv day 1, mitoxan-
trone 12 mg/m2 iv day 1 and prednisone 60 mg/m2 orally (po) for 5 days; eVACOP-B: doxo-
rubicin 50 mg/m2 and cyclophosphamide 350 mg/m2 iv weeks 1,5, and 9, oncovin 1.2
mg/m2 and bleomycin 10 U/m2 iv weeks 2, 4, 6, 8, 10 and 12, etoposide 50 mg/m2 iv and
100 mg/m2 po and doxorubicin 50 mg/m2 iv weeks 3, 7 and 11, prednisone 45 mg/m2 po
for 12 weeks; fMOPP-ABV: mechlorethamine 6 mg/m2 and oncovin 1.4 mg/m2 iv day 1,
procarbazine 100 mg/m2 po for 7 days, prednisone 40 mg/m2 po for 14 days, doxorubicin
35 mg/m2, bleomicyn 10 U/m2 and vinblastine 6 mg/m2 iv on day 8. 
*bone marrow involment
(8%) and grade III in 1 cycle (1%). In the 84
cycles performed thrombocytopenia caused a
delay or a dose reduction in two cycles. No
patient required Plt transfusion for thrombocy-
topenia.
Hemoglobin (Hb) count. The mean Hb counts
at the beginning of first and last chemotherapy
cycles were 13.8 g/dL (range 10.9-16 g/dL) and
10 g/dL (range 8.7-11.4 g/dL), respectively
(Table 2). The decrease in mean Hb counts was
significant (p < 0.0005). Despite the significant
decrease in mean Hb counts in the 84 cycles,
none of the patients required blood transfu-
sions for WHO grade III or IV anemia. 
Chemotherapy dose analysis. The mean actual
dose intensity was 92% (range 68-100%). An
actual dose intensity > 90% was given in 78% of
patients. Dose reduction and/or therapy delay
for leukopenia and/or thrombocytopenia
occurred in two patients (cases 3 and 5). Patient
number 5, despite G-CSF administration, expe-
rienced a total delay of 32 days. However, this
patient had been previously treated with other
cycles of chemotherapy. Patient #8 suffered a
delay of 13 days for herpes zoster infection at
the time of the second cycle of chemotherapy.
Patient #9 received G-CSF only at the end of the
third cycle. Before G-CSF administration this
patient had required a delay of 7 days for
leukopenia, but following G-CSF the same
patient experienced no further leukopenia-relat-
ed delays.
Infection. Despite severe neutropenia in 7
cycles, no one experienced fever (temperature
> 37.5°C for 1 hour) or documented infection
requiring intravenous antibiotics and hospital-
ization.
Safety of G-CSF administration. G-CSF was
well tolerated. No patient required transfusion
support. No increased incidence of WHO grade
III and IV mucositis was experienced, and no
changes in biochemical profile were detected.
Tumor response. Seven patients (78%) achieved
complete remission, while two (22%) suffered
disease progression.
Discussion
Patients with NHL and HD treated with dif-
ferent combinations of drugs at conventional
dosages rarely receive 100% of the planned
doses and neutropenia is the most important
factor negatively affecting the planning sched-
ule. G-CSF administered after chemotherapy
significantly reduces the severity of neutropenia
and the incidence of infections.9 In a recent ran-
domized study, G-CSF not only prevented neu-
tropenia but allowed the full dose of cytotoxic
drugs to be delivered without delays.10
The timing of G-CSF administration in rela-
tion to chemotherapy is still controversial.
Kinetic studies have shown that the prolifera-
tion status of progenitor cells significantly
increases within 48-72 hours of G-CSF treat-
ment.11,12 After discontinuance of colony stimu-
lating factors (CSFs), progenitor cells become
quiescent within 48-96 hours.12 In addition, sev-
eral data support the effect of G-CSF on multi-
potential progenitors in vivo.6 Proliferating
progenitor cells are more sensitive to cytotoxic
drugs and thus their proliferative status places
them at increased risk of massive depletion, pri-
marily when repeated cycles of chemotherapy
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Table 2. Mean absolute neutrophil counts (ANC), platelet counts (Plt) and
hemoglobin levels (Hb) before the first and last cycles of chemotherapy.
Delays in chemotherapy administration and actual dose intensity are shown
for each patient. 
B e f o r e  f i r s t  c y c l e B e f o r e  l a s t  c y c l e
Actual 
# ANC Plt Hb ANC Plt Hb Delay dose
(x109/L) (x109/L) (g/dL) (x109/L) (x109/L) (g/dL) (days) intensity 
(%)
1 2.5 192 13.8 1.4 223 10.5 0 100
2 4.5 309 13.7 3.0 566 10.4 0 100
3 4.5 320 16.0 3.4 254 11.4 0 92
4 3.9 338 13.7 3.4 104 10.6 0 100
5 4.8 236 15.6 5.5 271 9.2 32 68
6 4.8 236 15.4 5.5 271 9.9 2 98
7 6.7 203 10.9 3.7 131 8.7 7 96
8 4.3 236 11.3 6.3 172 9.8 13 93
9 4.8 279 13.5 5.2 270 9.9 7 82
M 4.5 261 13.8 4.1* 251° 10.0# 7 92
R 2.5-6.7 192-338 10.9-16.0 1.4-6.3 104-566 8.7-11.4 0-32 68-100
M: mean. R: range. 
*not significantly different when compared to pre-therapy values (p < 0.375). °not signif-
icantly different when compared to pre-therapy values (p > 0.4). #significantly different
when compared to pre-therapy values (p < 0.0005).
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and G-CSF are administered. These data suggest
that a wash-out period between chemotherapy
and G-CSF administration is necessary in order
to prevent the detrimental effect of chemothera-
py on actively proliferating progenitors.13
In our study we began giving G-CSF 48 hours
after chemotherapy and stopped 48 hours
before the subsequent chemotherapy treatment.
Using this schedule we found no detrimental
effect on neutrophil recovery in 84 cycles except
for one patient (#5) who had previously
received extensive chemotherapy. The mean
decrease in ANC and Plt counts, when pre-ther-
apy and post-therapy counts are compared, was
not significant (p < 0.375 and p > 0.4, respec-
tively).
Due to the high cost of CSF therapy and the
existence of a peak leukocyte count (data not
reported), the wash-out period between G-CSF
and chemotherapy should be adapted to each
chemotherapy schedule. In particular, when the
regimen is based on a 2-3-week interval between
cycles and the leukocyte count nadir cannot be
predicted, G-CSF should be administered close
to the nadir. In contrast, when chemotherapy
schedules are based on weekly administrations
and the leukocyte count nadir can not be pre-
dicted, our schedule of a 48-hour interval
between G-CSF and chemotherapy is recom-
mended.
According to randomized trials, chemothera-
py and G-CSF administration are able to induce
an increase in dose intensity.10 A recent study in
this journal has shown that G-CSF can allow
dose intensification even in patients with resis-
tant myeloma.14 Whether or not this increase
will have a clinical effect is still controversial.
Although the number of patients included in
this study is rather small, on the basis of our
results we believe that every attempt to intensify
chemotherapy by using CSF even in the stan-
dard dose setting, must take into account the
timing of CSF treatment. A wash-out period
between CSF treatment and chemotherapy is
necessary to prevent detrimental effects on
myelopoiesis as well as thrombopoiesis.
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